Welcome to our dedicated page for Essa Pharma SEC filings (Ticker: EPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates historical SEC filings for ESSA Pharma Inc. (former NASDAQ: EPIX), a British Columbia–incorporated pharmaceutical company that was previously focused on developing novel and proprietary therapies for patients with prostate cancer. These filings document ESSA’s regulatory history as a U.S.-reporting issuer and provide detailed information on the corporate steps that led to its acquisition by XenoTherapeutics Inc. and the delisting of its common shares.
Among the key documents available are multiple Forms 8-K reporting material events related to the Business Combination Agreement with XenoTherapeutics, the subsequent Amendment Agreement, and the consummation of the court-approved plan of arrangement under the Business Corporations Act (British Columbia). These filings describe the consideration received by ESSA shareholders, including cash payments and non-transferable contingent value rights (CVRs), as well as the company’s large return of capital distribution made as part of the discontinuance and winding-up of its business.
The filings also include a Form 25 (Form 25-NSE) filed by Nasdaq Stock Market LLC on October 9, 2025, which formally removes ESSA’s common stock from listing and registration on Nasdaq. Related 8-K disclosures explain ESSA’s request that Nasdaq suspend trading in its shares and the purchaser’s intention to file a Form 15 to terminate registration under Section 12(g) of the Exchange Act and suspend reporting obligations under Sections 13 and 15(d).
Using Stock Titan’s tools, readers can quickly locate ESSA’s quarterly and annual reports, current reports on Form 8-K, and transaction-related exhibits, while AI-powered summaries help interpret complex legal and financial language. This makes it easier to understand how the arrangement was structured, how shareholder votes and court approvals were obtained, and what the delisting and deregistration steps mean for the historical EPIX ticker and former ESSA securityholders.
ESSA Pharma Inc. filed a Post-Effective Amendment to its Form S-3 to withdraw and remove from registration any unissued and unsold securities previously registered for up to $200,000,000. This follows the completion of a business combination in which Xeno Acquisition Corp. acquired all outstanding common shares on October 9, 2025.
Shareholders received an initial cash distribution of $1.6910318 per share prior to closing and approximately $0.1242 per share at closing, plus one non-transferable CVR per share with the right to receive up to approximately $0.14 per CVR. The potential CVR pool totals up to $6.7 million, contingent on specified outcomes. As a result of the transaction, ESSA terminated all offerings under the registration and ended the effectiveness of the registration statement.
ESSA Pharma (EPIX) reported an insider transaction tied to its completed business combination. The company’s Chief Financial Officer disposed of 33,343 common shares on October 9, 2025, as all outstanding shares were acquired by Xeno Acquisition Corp. pursuant to the Business Combination Agreement.
Holders received approximately US$0.12 per share in cash plus one contingent value right (CVR) per share, which entitles the holder to receive up to approximately US$0.14 per CVR within specified periods after closing. Following the transaction, the reporting person beneficially owned 0 shares.
ESSA Pharma (EPIX) disclosed a Form 4 reflecting the completion of its sale on October 9, 2025. A reporting director disposed of 43,240 common shares, reducing beneficial ownership to 0 shares following the transaction.
Under the Business Combination Agreement among ESSA Pharma, XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation, all issued and outstanding common shares were acquired for
ESSA Pharma (EPIX) reported an insider Form 4 tied to its merger close. On October 9, 2025, all common shares were acquired by Xeno Acquisition Corp. under a Business Combination Agreement.
The reporting person disposed of 14,299 common shares, reducing beneficial ownership to zero. Holders received approximately
ESSA Pharma (EPIX) reported an insider transaction tied to its acquisition. On October 9, 2025, a director disposed of 30,002 common shares, reflecting the closing of a business combination in which all outstanding shares were acquired. Holders received approximately US$0.12 in cash per share plus one contingent value right (CVR) per share.
The CVR entitles the holder to receive up to approximately US$0.14 per CVR, payable within specified periods following the close. Following the transaction, the reporting person held 0 shares directly.
ESSA Pharma (EPIX) reported an insider transaction: President and CEO David Parkinson, also a director, disposed of 65,675 common shares on October 9, 2025. The transaction occurred in connection with a business combination under which the purchaser acquired all issued and outstanding common shares for approximately US$0.12 per share plus one CVR per share entitling holders to receive up to approximately US$0.14 per CVR.
Following the transaction, the filing lists 0 shares beneficially owned.
ESSA Pharma (EPIX) reported an insider transaction tied to its change of control. A director filed a Form 4 showing the disposition of 784,404 common shares on October 9, 2025, coinciding with the closing of a business combination.
According to the filing, Xeno Acquisition Corp. acquired all issued and outstanding ESSA common shares for approximately US$0.12 per share in cash plus one contingent value right (CVR) per share entitling holders to receive up to approximately US$0.14 per CVR within specified periods following closing.
ESSA Pharma (EPIX) director reports merger-related share disposition. A Form 4 shows the reporting person disposed of 2,881 common shares on 10/09/2025 in connection with a completed business combination. All issued and outstanding ESSA Pharma shares were acquired by Xeno Acquisition Corp. for approximately US$0.12 per share plus one contingent value right (CVR) per share.
Each CVR entitles its holder to receive up to approximately US$0.14 per CVR, payable within specified periods following closing. After the transaction, the reporting person beneficially owned 0 shares.
ESSA Pharma Inc. (EPIX) insiders affiliated with Biotechnology Value Fund entities reported share dispositions tied to the company’s merger. On
Per the terms, holders received
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
